Improved AAV tropism is essential for gene therapy to reach its full potential. New capsid ... engineering platform. More efficient delivery of therapeutic gene payloads with higher tissue and ...

(NYSE: BIO and BIO.B), announced the launch of Vericheck ddPCR™ Empty-Full Capsid ... for AAV vector characterization, driving the development of safe and effective gene therapies. “AAVs are widely ...

The capsid license follows an ... Naturally occurring AAV capsids lack precise targeting to deliver medicine to the right cells, are difficult to manufacture, and have pre-existing immunity.

Gene therapy could potentially cure genetic diseases, but it remains a challenge to package and deliver new genes to specific ...

In this talk, David Apiyo, Manager of Application Development at Sartorius (Göttingen, Germany), proposes a method that extends the use of AAVX biosensors to determine empty-to-full capsid ratios.

While naturally occurring AAV capsids lack precise targeting to deliver medicine to the right cells ... vector engineering by generating high-performance out-of-distribution capsid proteins.